Company Overview of Q Therapeutics, Inc.
Q Therapeutics, Inc., a clinical-stage company, engages in developing human cell-based therapies intended to treat neurodegenerative diseases of the brain and spinal cord. Its product candidate includes Q-Cells that are healthy human glial progenitor cells intended to restore or preserve normal activity of neurons by providing support functions that occur in healthy central nervous system (CNS) tissues. The company develops Q-Cells for application in a range of CNS diseases, including multiple sclerosis, transverse myelitis, cerebral palsy, and stroke, as well as other neurodegenerative diseases and injuries, such as amyotrophic lateral sclerosis, Huntington’s disease, spinal cord injury, st...
615 Arapeen Drive
Salt Lake City, UT 84108
Key Executives for Q Therapeutics, Inc.
President, CEO & Chairman of the Board
Scientific Co-Founder, Chief Strategy Officer & Chairman of the Scientific Advisory Board
Vice President of Research & Development
Compensation as of Fiscal Year 2017.
Q Therapeutics, Inc. Key Developments
Q Therapeutics, Inc. Announces Research Collaboration with REPROCELL Inc
Dec 13 17
Q Therapeutics, Inc. announced a collaborative research agreement with REPROCELL Inc. that combines each company’s proprietary technologies to develop new iPS cell (IPSC) therapies for central nervous system (CNS) diseases. Q Therapeutics has patented a process to manufacture glial-restricted progenitor (GRP) cells from any tissue source. GRPs have been proven safe and effective in several pre-clinical CNS disease models. Q Therapeutics has obtained Investigational New Drug (IND) clearance from the FDA in Amyotrophic Lateral Sclerosis and Transverse Myelitis (both orphan indications) for its adult cell product, Q-CELLS™. REPROCELL has developed a proprietary process to manufacture integration-free, virus-free and clinically relevant human iPSC lines using proprietary RNA reprogramming technology. This process is suitable for manufacturing robust, consistent and high quality functional cells at commercial scale. Combining these technologies will enable rapid generation of therapeutic-grade, iPSC-derived GRPs to generate safety and efficacy data in preclinical disease models. Q Therapeutics’ expertise in obtaining regulatory approval in the United States and REPROCELL’s ongoing clinical partnerships in Japan enable them to work toward approval of IPSC-derived products on a global scale.
Q Therapeutics, Inc. Appoints Tom Parks as Independent Member to Its Board of Directors
Aug 7 17
Q Therapeutics, Inc. announced the appointment of Tom Parks, Ph.D. as an independent member to the Company's Board of Directors. In addition, Dr. Parks has agreed to serve on the Board's Nominating and Governance Committee; and will be joined on the Committee by current independent directors, Peter Barton Hutt, Peter Grebow, and Hunter Jackson. He currently serves on the boards of Navigen Pharmaceuticals Inc., SentrX Animal Care Inc., and ConusRx Inc.
FDA Allows Q Therapeutics, Inc.'s Q-Cells(R) for First-In-Human Transverse Myelitis Trial
Jul 25 17
Q Therapeutics, Inc. announced U.S. Food and Drug Administration (FDA) allowance of its Investigational New Drug (IND) application to proceed with a Phase 1/2a clinical trial of Q-Cells in patients with Transverse Myelitis. TM is a crippling inflammation of the spinal cord that affects approximately 30,000 people in the United States, with more than 1,700 new cases diagnosed each year. Similar to Multiple Sclerosis (MS), TM destroys the myelin sheath surrounding nerve fibers in the spinal cord, compromising muscle control and affecting sensation. Q-Cells are human glial-restricted progenitor cells (GRPs) and the company's first patented cellular therapeutic candidate. As reported in the May 2017 issue of Experimental Neurology, Piotr Walczak, MD, PhD, and his team at The Johns Hopkins University showed that Q-Cells exert a robust therapeutic effect when transplanted into the CNS of animals born unable to produce healthy myelin. The Q-Cells performed multiple repair and support functions resulting in myelination and restoration of animals to normal function with extended life span. These data, along with other published pre-clinical data from animal models of CNS disease and injury, show that delivering healthy glial cells into the brain and spinal cord can alter the course of currently incurable CNS conditions. Collaborative development of the Q-Cells therapeutic approach with Dr. Walczak and Nicholas Maragakis, MD of The Johns Hopkins University has received substantial support from the National Institute of Neurological Disorders and Stroke Translational Research Program (U01-NS06713) and the Maryland Stem Cell Research Fund. Q Therapeutics worked with MPI Research, Inc., to carry out preclinical safety studies, Goodwin Biotechnology, Inc., to manufacture the antibody used in cell purification, and Biologics Consulting Group for regulatory guidance. The company also partnered with the Cell Therapy and Regenerative Medicine Facility (CTRM) at the University of Utah in developing Good Manufacturing Processes to create the clinical-grade product.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|